NCT07354516

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

← Hub

Registry fields

Overall status: COMPLETED
Conditions: OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Study type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Primary purpose: TREATMENT
Intervention type: COMBINATION_PRODUCT, DRUG
Interventions: QLS-111-FDC, Latanoprost (0.005%)
Lead sponsor: Qlaris Bio, Inc. (INDUSTRY)

Cached at: 2026-07-30 19:25:11

View on ClinicalTrials.gov

Brief summary

Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report